# History and Physical

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Yul Brynner (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML020-SYN
- Date: 2026-09-01
- Fictional facility: St. Posthumous Health Center
- Fictional author: Simon Achterberg, MD
- Calendar frame: modern shifted

## Reason for visit

New patient visit for six weeks of hoarseness, with a left upper lobe mass on same-day CT. **S**

## Historical basis

- Yul Brynner was born Yuliy Borisovich Bryner on July 11, 1920, in Vladivostok, Russia. **D**
- He gave varying accounts of his origins, saying at times that he was born on Sakhalin Island, with the year given as 1915 (UPI gives July 11, 1915; another reference gives July 12, 1915, under the name Taidje Kahn). **D**
- He first played the King of Siam in The King and I on Broadway in 1951, won the Academy Award for best actor in the 1956 film, and played the role 4,625 times over 34 years. **D**
- He smoked heavily for decades: UPI reported that at one time he smoked five packs of cigarettes a day, and Cancer Today reports two to four packs a day from the age of 12 and that he quit in 1971. **D**
- In September 1983 he was found to have lung cancer; Cancer Today reports that he had found a lump on his vocal cords and that the tumor was too close to his heart for surgery, and UPI reports that he was treated for lung cancer that month and said he would beat the disease and resume touring. **D**

4 later historical claims are omitted because they describe events after the index age. See the teaching note.

These claims are historical evidence, not findings from a real modern examination.

## History of present illness

This fictional modern episode addresses the presenting concerns below. **S**

- His voice has become weak and breathy, and he cannot sing or project on stage. **S**
- He wants to get back to performing and to keep working for as long as he can. **S**
- He wants people to know what smoking did to him. **S**

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Medications and allergies

- No medications before this visit. **S**
- No known allergy **S**

## Past medical history

True biography with historical dates; these events are not part of the synthetic care timeline.

- 1971: Heavy cigarette smoking for decades, quit twelve years before the index visit **D** (CLM-0004)

## Procedures and immunizations

- 2026-09-01 to 2026-09-01: Flexible laryngoscopy by the ENT surgeon: left vocal fold immobile in the paramedian position with incomplete glottic closure; no laryngeal mass or mucosal lesion **S**
- 2026-09-01 to 2026-09-01: CT of the chest, abdomen, and pelvis with contrast: 5.2 cm left upper lobe mass invading the mediastinal fat of the aortopulmonary window and abutting the aortic arch and left pulmonary artery; enlarged aortopulmonary window (2.4 cm) and subcarinal (1.8 cm) lymph nodes; a small lytic lesion in the T10 vertebral body; no adrenal or liver lesion **S**
- 2025-10-21: Influenza vaccine, 2025-2026 season **S**
- 2020-03-17: Tdap vaccine **S**

## Family history

- No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.

## Measurements

Hemoglobin: 13.8 g/dL; White cell count: 7.9 10*3/uL; Platelets: 290 10*3/uL; Sodium: 138 mmol/L; Potassium: 4.3 mmol/L; Creatinine: 0.9 mg/dL; eGFR: 92 mL/min/1.73 m²; Calcium: 9.6 mg/dL; Albumin: 4 g/dL; ALT: 24 U/L; AST: 22 U/L; Alkaline phosphatase: 98 U/L; Total bilirubin: 0.6 mg/dL; Glucose: 96 mg/dL; PHQ-9: 5. All results are synthetic.

BP 132/80 mmHg; pulse 82 bpm; respirations 16/min; temperature 36.8 °C; oxygen saturation 96% on room air; weight 72.4 kg; BMI 22.9 kg/m². All vital signs are synthetic.

## Examination

Mental status: Alert, commanding, and precise; wants the facts plainly and in full; Worried but composed; PHQ-9 score 5 with item 9 scored 0; no thoughts of suicide or self-harm. Functional status: ECOG performance status 1: fully active offstage, but tires by the end of an evening and has stopped singing because of the weak voice; walks briskly without breathlessness on the level; climbs two flights with mild breathlessness. Physical examination is intentionally limited. **S**

## Assessment

1. Left vocal fold paralysis with a breathy, weak voice, most likely from left recurrent laryngeal nerve involvement by disease in the aortopulmonary window; status draft. **S**
2. Left upper lobe mass invading the mediastinum, with enlarged mediastinal lymph nodes, on CT at presentation; suspicious for lung cancer pending tissue diagnosis; status draft. **S**
3. Former smoker: about 3 packs a day from age 12 until he quit 12 years ago, roughly 115 pack-years; no tobacco since; status draft. **S**

## Plan

- Thoracic oncology consultation for the tissue diagnosis, stage, biomarker plan, first-line therapy, the place of radiation and a bone-modifying agent, and monitoring. Guideline: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026) **S**
- Staging and tissue diagnosis: FDG PET-CT, brain MRI with contrast, and endobronchial ultrasound-guided needle aspiration of the highest-stage node, with enough tissue for PD-L1 and comprehensive next-generation sequencing, and plasma cell-free DNA testing in parallel. Guideline: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026) **S**
- If bone metastases are confirmed: zoledronic acid 4 mg every 12 weeks after a dental examination, with calcium and vitamin D and calcium and creatinine checks before each dose; palliative radiation only if a lesion becomes painful or threatens fracture. Guideline: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026) **S**
- Tobacco: confirm abstinence at each visit; no cessation treatment needed; record the smoking history for his care team. Guideline: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026) **S**

## Guideline basis

- CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026), Aether Forge
- NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026), National Comprehensive Cancer Network
